

From Research to the Pharmaceutical Market. Performance systems and pulling factors

FARMAINDUSTRIA



BioSpain


Seville, September 26th 2018

Pharma-Biotech Program

- **Farmaindustria initiated this program in 2011 under Spanish Technological Platform on Innovative Medicines.**
- **The main goal** is to promote further collaboration and partnership among the pharmaceutical industry and the biomedical research world.
- **To seek projects with real capacity to offer a high innovative** and with reasonable expectations of achieving commercial success in the medium term.

Pharma-Biotech Program

- According to the data from the follow-up survey (april 2018), **41 % of selected projects in pharma-biotech's session are no longer active.** Due to i) lack of funding (74%) and ii) unsatisfactory results (26%).
- **59% active projects.** i) with great progress (73%) and ii) without relevant progress (27%). More details in the figure:



Workshop Objectives

- This workshop will debate why the **economic and industrial rates in Spain are lower** than expected when it comes to R&D efforts.
- The role of the currently **existing systems** to improve fluency and effectiveness among different stakeholders.
- Some **examples of experiences** will be given from both the basic researchers and industry's view

Workshop Objectives

- ➊ This session will be organized into two different panels, each of them lasting 75 minutes. Each speaker has 10 minutes. After, there will be an open discussion for 15 minutes.
- ➋ Panel 1: Performance Systems
- ➌ Panel 2: Pharmaceutical Industry “pulling” effect.

Workshop Objectives. Performance Systems

- Research networks as efficient transfer systems. Current capability and growth expectations. **Carlos Diéguez** (CIBEROBN, CIMUS)
- Traslation of Biomedical Research from the Academy: where do we stand? **Manuel Fresno** (Universidad Autónoma de Madrid)
- Are there any appropriate systems? What do they need to be more effective? **Francisca Vicente** (Fundación Medina)
- What is required to draw the attention of the right investors? **Miguel Vega** (Allinky)
- What does a biomedical research project in Spain need to overtake the “Death Valley” of basic research and reach clinical reaserch? **Alfonso Beltrán** (FIPSE-ISCIii)
- Some figures on biomedical research transfer, in Spain an internationally: reasons for the differences. **Raúl Martín** (Ysios Capital)

Workshop Objectives. Pharmaceutical industry “pulling” effect

- There is a well known situation diagnosis but there are still effective means missing for results transfer. Why? Some ideas. **Andrés G. Fernández** (Ferrer)
- Open Innovation from Big Pharma: the J&J approach. **Antonio Gómez** (Janssen Cilag)
- Innovation strategies and creation of scientific networks. **María Ángeles Martínez-Grau** (Lilly)
- Preclinical research collaborations in the pharmaceutical industry: incentives and barriers. **Arsenio Nueda** (Almirall)
- Diseases of the Devolving World. Open Lab’s experience in Spain. **José Fiandor** (GSK)
- From Academic Ideas to Industrial Application-Max Planck’s Lead Discovery Center as a Model for a Translational Incubator. **Peter Nussbaumer** (Max Planck’s Lead Discovery Center)